4D Molecular Therapeutics Inc. Common Stock (FDMT)
Stock · NASDAQ · Health Care
$14.65as of 8/28/2026
Price chart
Open in TradingViewActive signals
Support level
$9.4
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
About FDMT
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Website
- 4dmoleculartherapeutics.com/
Fundamentals
- Market cap
- $551.51M
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- $-2.70
- Dividend yield
- —
- Beta
- 2.78
- Avg. volume
- —
52-week range
$5.97$16.93
How 4D Molecular Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 18, 2026 · via SEC EDGAR / Finnhub
4D Molecular Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- FDMT4D Molecular Therapeutics Inc. Common Stock$14.65▼ 1.74%Market cap $551.51MP/E —$5.97$16.93
- ZURAZura Bio Limited Class A Ordinary Shares$5.73▼ 2.05%Market cap $542.44MP/E —$1.88$7.44
- PRMEPrime Medicine Inc. Common Stock$3.62▼ 0.69%Market cap $532.82MP/E —$2.67$6.94
- TECXTectonic Therapeutic Inc. Common Stock$35.69▼ 2.75%Market cap $570.23MP/E —$14.39$39.53
- AUTLAutolus Therapeutics plc American Depositary Share$2.34▼ 1.06%Market cap $532.31MP/E —$1.18$2.58
- DNAGinkgo Bioworks Holdings Inc. Class A Common Stock$6.98▼ 3.93%Market cap $528.15MP/E —$5.37$17.58
- PROKProKidney Corp. Class A Ordinary Shares$1.84▲ 1.10%Market cap $495.38MP/E —$1.3$3.48
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| FDMT 4D Molecular Therapeutics Inc. Common Stock | $551.51M | — | $14.65 | ▼ 1.74% | $5.97$16.93 |
| ZURA Zura Bio Limited Class A Ordinary Shares | $542.44M | — | $5.73 | ▼ 2.05% | $1.88$7.44 |
| PRME Prime Medicine Inc. Common Stock | $532.82M | — | $3.62 | ▼ 0.69% | $2.67$6.94 |
| TECX Tectonic Therapeutic Inc. Common Stock | $570.23M | — | $35.69 | ▼ 2.75% | $14.39$39.53 |
| AUTL Autolus Therapeutics plc American Depositary Share | $532.31M | — | $2.34 | ▼ 1.06% | $1.18$2.58 |
| DNA Ginkgo Bioworks Holdings Inc. Class A Common Stock | $528.15M | — | $6.98 | ▼ 3.93% | $5.37$17.58 |
| PROK ProKidney Corp. Class A Ordinary Shares | $495.38M | — | $1.84 | ▲ 1.10% | $1.3$3.48 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →Acquired
216.4K
Disposed
228.7K
- David Kirn · August 4, 2026 · Sale26.8K @ $10.23
- David Kirn · August 3, 2026 · Sale12.4K @ $10.05
- David Kirn · July 10, 2026 · Sale442 @ $12.84
- David Kirn · July 10, 2026 · Sale15.3K @ $12.01
- David Kirn · July 9, 2026 · Sale42.6K @ $12.87
- Scott Bizily · June 30, 2026 · Option Exercise5.8K @ $6.49
- Scott Bizily · June 30, 2026 · Option Exercise814 @ $4.14
- Scott Bizily · June 30, 2026 · Sale6.6K @ $14
- Scott Bizily · June 23, 2026 · Option Exercise9.8K @ $4.14
- Scott Bizily · June 23, 2026 · Sale9.8K @ $12
- David Kirn · June 22, 2026 · Sale114.7K @ $10.47
- Nancy Miller-Rich · June 17, 2026 · Grant50.0K
- GRAY SUSANNAH · June 17, 2026 · Grant50.0K
- Charles Theuer · June 17, 2026 · Grant50.0K
- Shawn Tomasello · June 17, 2026 · Grant50.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 48.21M
- Total value held
- $447.40M
- Institutional holders
- 147
Top holders this quarter
- Unknown5.25M
- Unknown5.05M
- Unknown4.21M
- Unknown4.15M
- Unknown3.65M
- Unknown2.88M
- Unknown2.71M
- Unknown2.00M
- Unknown1.61M
- Unknown1.43M
See the full, filterable feed with live charts on the MarketWall dashboard.